103 related articles for article (PubMed ID: 10469214)
1. p53 expression, p21 expression and the apoptotic index in endometrioid endometrial adenocarcinoma.
Burton JL; Stewart RL; Heatley MK; Royds JA; Wells M
Histopathology; 1999 Sep; 35(3):221-9. PubMed ID: 10469214
[TBL] [Abstract][Full Text] [Related]
2. Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.
Edmondson RJ; Crosbie EJ; Nickkho-Amiry M; Kaufmann A; Stelloo E; Nijman HW; Leary A; Auguste A; Mileshkin L; Pollock P; MacKay HJ; Powell ME; Bosse T; Creutzberg CL; Kitchener HC
Gynecol Oncol; 2017 Aug; 146(2):327-333. PubMed ID: 28511869
[TBL] [Abstract][Full Text] [Related]
3. TP53 overexpression in recurrent endometrial carcinoma.
Pijnenborg JM; van de Broek L; Dam de Veen GC; Roemen GM; de Haan J; van Engeland M; Voncken JW; Groothuis PG
Gynecol Oncol; 2006 Feb; 100(2):397-404. PubMed ID: 16271749
[TBL] [Abstract][Full Text] [Related]
4. Expression of COX-2, Ki-67, cyclin D1, and P21 in endometrial endometrioid carcinomas.
Cao QJ; Einstein MH; Anderson PS; Runowicz CD; Balan R; Jones JG
Int J Gynecol Pathol; 2002 Apr; 21(2):147-54. PubMed ID: 11917224
[TBL] [Abstract][Full Text] [Related]
5. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level.
Alkushi A; Lim P; Coldman A; Huntsman D; Miller D; Gilks CB
Int J Gynecol Pathol; 2004 Apr; 23(2):129-37. PubMed ID: 15084841
[TBL] [Abstract][Full Text] [Related]
6. Correlations between p21 expression and clinicopathological findings, p53 gene and protein alterations, and survival in patients with endometrial carcinoma.
Ito K; Sasano H; Matsunaga G; Sato S; Yajima A; Nasim S; Garret CT
J Pathol; 1997 Nov; 183(3):318-24. PubMed ID: 9422988
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral heterogeneous expression of p53 correlates with p53 mutation, Ki-67, and cyclin A expression in endometrioid-type endometrial adenocarcinomas.
Feng YZ; Shiozawa T; Horiuchi A; Shih HC; Miyamoto T; Kashima H; Suzuki A; Nikaido T; Konishi I
Virchows Arch; 2005 Nov; 447(5):816-22. PubMed ID: 16021509
[TBL] [Abstract][Full Text] [Related]
8. p53 protein in endometrial cancer is related to proliferative activity and prognosis but not to expression of p21 protein.
Backe J; Gassel AM; Hauber K; Krebs S; Bartek J; Caffier H; Kreipe HH; Müller-Hermelink HK; Dietl J
Int J Gynecol Pathol; 1997 Oct; 16(4):361-8. PubMed ID: 9421076
[TBL] [Abstract][Full Text] [Related]
9. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
Lax SF; Pizer ES; Ronnett BM; Kurman RJ
Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
[TBL] [Abstract][Full Text] [Related]
10. Direct sequencing of the p53 gene shows absence of mutations in endometrioid endometrial adenocarcinomas expressing p53 protein.
Stewart RL; Royds JA; Burton JL; Heatley MK; Wells M
Histopathology; 1998 Nov; 33(5):440-5. PubMed ID: 9839168
[TBL] [Abstract][Full Text] [Related]
11. Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27.
An HJ; Lee YH; Cho NH; Shim JY; Kim JY; Lee C; Kim SJ
Histopathology; 2002 Nov; 41(5):437-45. PubMed ID: 12405911
[TBL] [Abstract][Full Text] [Related]
12. Aromatase, cyclooxygenase 2, HER-2/neu, and p53 as prognostic factors in endometrioid endometrial cancer.
Jongen VH; Briët JM; de Jong RA; Joppe E; ten Hoor KA; Boezen HM; Evans DB; Hollema H; van der Zee AG; Nijman HW
Int J Gynecol Cancer; 2009 May; 19(4):670-6. PubMed ID: 19509570
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers and microsatellite instability analysis of curettings can predict the behavior of FIGO stage I endometrial endometrioid adenocarcinoma.
Steinbakk A; Malpica A; Slewa A; Skaland I; Gudlaugsson E; Janssen EA; Løvslett K; Fiane B; Kruse AJ; Feng W; Yinhua Y; Baak JP
Mod Pathol; 2011 Sep; 24(9):1262-71. PubMed ID: 21552210
[TBL] [Abstract][Full Text] [Related]
14. Adenovirus-mediated expression of p53 or p21 in a papillary serous endometrial carcinoma cell line (SPEC-2) results in both growth inhibition and apoptotic cell death: potential application of gene therapy to endometrial cancer.
Ramondetta L; Mills GB; Burke TW; Wolf JK
Clin Cancer Res; 2000 Jan; 6(1):278-84. PubMed ID: 10656459
[TBL] [Abstract][Full Text] [Related]
15. Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and Rb), and cyclin E in uterine endometrioid carcinoma.
Li SF; Shiozawa T; Nakayama K; Nikaido T; Fujii S
Cancer; 1996 Jan; 77(2):321-9. PubMed ID: 8625241
[TBL] [Abstract][Full Text] [Related]
16. p53 aberrations in low grade endometrioid carcinoma of the endometrium with nodal metastases: possible insights on pathogenesis discerned from immunohistochemistry.
Fadare O; Parkash V
Diagn Pathol; 2017 Nov; 12(1):81. PubMed ID: 29137657
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical expression of the p53, mdm2, p21/Waf-1, Rb, p16, Ki67, cyclin D1, cyclin A and cyclin B1 proteins and apoptotic index in T-cell lymphomas.
Kanavaros P; Bai M; Stefanaki K; Poussias G; Rontogianni D; Zioga E; Gorgoulis V; Agnantis NJ
Histol Histopathol; 2001 Apr; 16(2):377-86. PubMed ID: 11332692
[TBL] [Abstract][Full Text] [Related]
18. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
19. P21 (WAF1) expression in colorectal cancer: correlation with P53 and cyclin D1 expression, clinicopathological parameters and prognosis.
Pasz-Walczak G; Kordek R; Faflik M
Pathol Res Pract; 2001; 197(10):683-9. PubMed ID: 11700890
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of overexpression of p53 in uterine endometrioid adenocarcinomas with an analysis of nuclear grade.
Urabe R; Hachisuga T; Kurita T; Kagami S; Kawagoe T; Matsuura Y; Shimajiri S
J Obstet Gynaecol Res; 2014 Mar; 40(3):812-9. PubMed ID: 24246002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
